Mexicor caps. 100mg 20 pieces

Description

Composition
Active substance:
emoxypine in terms of 100% substance – 100 mg;
Excipients:
potato starch – 54.5 mg, povidone (polyvinylpyrrolidone, low molecular weight medical 12600 ± 2700) – 4.0 mg, lactose (milk sugar) – 40.0 mg Magnesium stearate – 0.5 mg Microcrystalline cellulose – 1.0 mg; hard gelatin capsules № 2 (gelatin – 59.3189 mg Titanium dioxide E171 – 1.22 mg, sunset yellow colorant E110 – 0.0036 mg, quinoline yellow colorant E104 – 0.4575 mg).
Description:
Hard gelatin capsules № 2 yellow. The contents of capsules – granules comprising granules and a powder of white or white color with a yellowish tinge.
Product form:
Capsules 100 mg. 10 capsules in blisters of PVC film and aluminum foil. 2 contour packaging together with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity to the active agent or other components of the formulation;
acute liver failure;
acute renal failure;
Children under 18 years of age (safety and efficacy of the drug in children has not been studied);
pregnancy;
breastfeeding;
rare hereditary galactose intolerance, lactase deficiency syndrome glucose-galactose malabsorption (formulation contains lactose).
Carefully
Impaired liver function, renal function (limited experience medical use).
Dosage
100 mg
Indications
Coronary heart disease (in the complex therapy);
The consequences of stroke, including after transient ischemic attacks, subcompensation phase as prophylactic courses;
Mild traumatic brain injury, the effects of traumatic brain injury;
Encephalopathies of various origins (discirkulatornaya, dysmetabolic, posttraumatic mixed);
Functional disorders of the autonomic nervous system (autonomic dystonia syndrome);
Mild cognitive impairment atherosclerotic;
Anxiety disorders in neurotic and neurosis-like states;
Relief of abstinence syndrome in alcoholism with prevalence of neurosis and vegetative-vascular disorders, postabstinentnom disorder;
State after acute intoxication antipsychotics;
Asthenic conditions, as well as for the prevention of systemic diseases under the influence of extreme factors and loads;
Exposure to extreme (stress) factors.
Interaction with other drugs
The drug enhances the action of benzodiazepine anxiolytics, antidepressants, anticonvulsants, and antiparkinsonian. It reduces the toxic effects of ethanol.
Before the appointment of the drug should be carefully collected Meksikor® drug history of the patient to assess the potential of drug interactions.
Overdose
Due to the low toxicity of the drug overdose unlikely. Information on cases of missing drug overdose. In case of overdose, you may experience symptoms of sleep disorders – drowsiness, insomnia. Treatment is symptomatic.
pharmachologic effect
Pharmacological group:
antioxidant agent
Pharmacodynamics:
Emoxypine has antioxidant, anti-hypoxic, anti-ischemic, membranoprotektornym, nootropic, stress-protective, anticonvulsant, anxiolytic effects.
Preparation improves resistance of the organism to the action of various damaging factors with the oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular accidents, ischemic heart disease, intoxication with ethanol and the state after intoxication antipsychotics). The drug reduces the manifestations of oxidative stress and inhibit free radical lipid peroxidation, increases the activity of superoxide dismutase. Modulates the activity of membrane enzymes – calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase receptor complexes (benzodiazepine, GABA, acetylcholine) that enhances their ability to bind to ligands, helps preserve the structural and functional organization of biological membranes, improves the transport of neurotransmitters and synaptic transmission. Increases the concentration of dopamine in the brain.
The drug causes increased compensatory activity of aerobic glycolysis and thereby reducing the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, with increasing content of adenosine triphosphate, creatine phosphate and activation energosinteziruyuschih mitochondrial functions, stabilization of cell membranes.
Energosinteziruyuschy effect of the drug is associated with an increase in delivery and consumption succinate cells implementation succinic acid succinate rapid oxidation phenomenon, as well as with the activation of the mitochondrial respiratory chain. When emoxypine dissociation in the cell and on the succinate derivative of 3-hydroxypyridine (base), the base exhibits antioxidant effect, stabilizing cell membranes and restores functional activity of cells.
Preparation improves the functional state of ischemic myocardium in myocardial infarction improves the contractility of the heart function, and reduces the appearance of systolic and diastolic left ventricular dysfunction. Normalises metabolic processes in the ischemic myocardium reduces the zone of necrosis, electrical activity and restores the contractility of the myocardium and increases collateral blood supply, activating energosinteziruyuschie processes in the area of ​​ischemia and promoting preservation of the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility with reversible cardiac dysfunction, which is a significant reserve for increasing cardiac contractility in patients with coronary heart disease.
Patients with stable angina increases exercise tolerance and antianginal activity nitropreparatov, improve blood rheology, reduce platelet aggregation and the consequences of reperfusion syndrome in acute coronary insufficiency. It has hypolipidemic effect, reduces total cholesterol and low density lipoproteins.
Improves cerebral blood flow and cerebral metabolism, improves blood circulation, prevents the decrease in cerebral blood flow after ischemia reperfusion period. Prevents post-ischemic drop in utilization of glucose and oxygen by the brain and prevents the progressive accumulation of lactate. The drug has a selective, not accompanied by sedation and muscle relaxation, anxiolytic effect, eliminates anxiety, fear, stress, anxiety, increases the adaptation and emotional status.
The effectiveness of the drug in the stressful effects manifested in normalizing behavior after stress, psycho-vegetative disorders, restoration of the sleep-wake cycles, mnemonic functions, learning processes, reducing the structural changes of the brain substance. The preparation is characterized by a pronounced effect when antitoxic withdrawal syndrome. Eliminates neurological manifestations of acute alcohol intoxication, restores behavioral, autonomic function, as well as capable of reducing the cognitive impairment caused by prolonged use of ethanol. Influenced emoxypine enhanced action tranquilizing, neuroleptic, anti-depressant, hypnotics and anticonvulsants, to reduce their dose and reduce side effects.
Pharmacokinetics:
Absorption
Quickly absorbed by ingestion. The maximum concentration at doses of 400 – 500 mg of 3.5 – 4.0 g / ml.
Distribution
Rapidly distributed to organs and tissues. The average retention time of drug in the body when taken orally – 4.9 – 5.2 hours.
Metabolism
It is metabolized in the liver by glyukuronkonyugirovaniya. 5 metabolites have been identified: 3-hydroxypyridine phosphate – is produced in the liver and involvement of alkaline phosphatase decomposes to phosphoric acid, and 3-hydroxypyridin; 2nd metabolite – a pharmacologically active, is formed in large quantities and is found in the urine at 1 – 2 days after admission; Third – is displayed in large amounts in the urine; 4 th and 5 th -glyukuronkonyugaty.
breeding
The half-life T1 / 2 when taken orally – 2.0 -. 2.6 h rapidly excreted in the urine primarily as metabolites in small quantities – unchanged. The most extensively excreted within the first 4 hours after ingestion. Indicators excretion in the urine unchanged drug and metabolites are high individual variability.
Pregnancy and breast-feeding
Use of the drug Meksikor® contraindicated in pregnancy (no evidence of clinical trials of the drug when used in pregnancy) and during breastfeeding. Breastfeeding should be terminated prior to ingestion.
Conditions of supply of pharmacies
Prescription.
side effects
May cause allergic reactions (including systemic allergic reaction), dyspeptic disorders (nausea, dry mouth, diarrhea), which quickly disappear on their own, or to remove the drug. With prolonged use may be a manifestation of flatulence, sleep disturbances (drowsiness or disturbance of sleep).
special instructions
Due to the presence of the drug Meksikor® lactose, the use of the drug is contraindicated in patients with rare hereditary galactose intolerance, lactase deficiency, glucose-galactose malabsorption.
The drug in the composition comprises excipients and colorants may be the cause of allergic reactions (including systemic). If signs of allergic reactions of the drug should be stopped immediately.
In patients with renal impairment or hepatic drug should be used with caution, performing periodic monitoring performance of the kidneys and liver.
There is no experience with the drug in children under the age of 18 years, during pregnancy and lactation (see. Section “Contraindications”).
Effect of the drug on the ability to drive, the mechanisms
During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
Stored in a dry place, protected from light at a temperature not higher than 25 ° C. Keep out of reach of children.
Dosing and Administration
Coronary heart disease (in the complex therapy):
Inside. Started treatment with a dose of 100 mg (1 tablet) 1-2 times a day, if necessary, gradually increasing the dosage depending on the therapeutic effect and tolerability of the treatment. The maximum daily dose should not exceed 800 mg (eight capsules), the maximum single dose – 200 mg (two capsules). The daily dose should be distributed into 2-3 doses throughout the day. Treatment with Meksikor® stopped gradually reducing the daily dose by 100 mg (1 capsule). Typically, the duration of the course of treatment Meksikor® in coronary heart disease is at least 1,5-2 months. However, dose, duration of treatment and the need for repeated courses of therapy must be individually installed doctor, based on the therapeutic effect and tolerability.
The consequences of stroke; mild head injury, the effects of traumatic brain injury; encephalopathies of various origins; functional disorders of the autonomic nervous system; mild cognitive disorders of atherosclerotic; anxiety disorders in neurotic and neurosis-like states; state after acute intoxication antipsychotics; asthenic states; exposure to extreme (stress) factors:
Inside. Started treatment with a dose of 100 mg (1 tablet) 1-2 times a day, if necessary, gradually increasing the dosage depending on the therapeutic effect and tolerability of the treatment. The maximum daily dose should not exceed 800 mg (eight capsules), the maximum single dose – 200 mg (two capsules). The daily dose should be distributed into 2-3 doses throughout the day. Treatment with Meksikor® stopped gradually reducing the daily dose by 100 mg (1 capsule). Typically the duration of the course of treatment Meksikor® for the above indications for use of 2-6 weeks. However, the dose and duration of treatment must be individually established physician, based on the therapeutic effect and tolerability.
Relief of abstinence syndrome in alcoholism with prevalence of neurosis and vegetative-vascular disorders, postabstinentnom disorders:
Inside. Started treatment with a dose of 100 mg (1 tablet) 1-2 times a day, if necessary, gradually increasing the dosage depending on the therapeutic effect and tolerability of the treatment. The maximum daily dose should not exceed 800 mg (eight capsules), the maximum single dose – 200 mg (two capsules). The daily dose should be distributed into 2-3 doses throughout the day. Treatment with Meksikor® stopped gradually reducing the dose for 2-3 days. duration of the course of treatment usually Meksikor® for the purpose of relief of withdrawal symptoms of alcoholism is 5-7 days. However, the dose and duration of treatment must be individually established physician, based on the therapeutic effect and tolerability.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist